GSK wins appeal to only pay AstraZeneca royalties on some sales of cancer drug Zejula
A panel of judges on the UK civil court of appeals agreed that GSK subsidiary Tesaro doesn’t have to pay royalties …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
